EP3672591

SYNERGISTIC ANTITUMOR EFFECT OF BCL-2 INHIBITOR COMBINED WITH RITUXIMAB AND/OR BENDAMUSTINE OR BCL-2 INHIBITOR COMBINED WITH CHOP

  • :
    EP einkaleyfi: Þýðing ekki lögð inn
  • :
    22.7.2019
  • :
    14.2.2024
  • :
    19845466.2
  • :
    21.7.2039
  • :
    SYNERGISTIC ANTITUMOR EFFECT OF BCL-2 INHIBITOR COMBINED WITH RITUXIMAB AND/OR BENDAMUSTINE OR BCL-2 INHIBITOR COMBINED WITH CHOP

22.7.2019
14.2.2024
  • :
    Ascentage Pharma (Suzhou) Co., Ltd.
  • :
    Unit 701, Building B7, 218 Xinghu Street Suzhou Industrial Park, Suzhou, Jiangsu 215000, CN
  • :
    YANG, Dajun
  • :
    Suzhou, Jiangsu 215000, CN
  • :
    ZHAI, Yifan
  • :
    Suzhou, Jiangsu 215000, CN
  • :
    WANG, Guangfeng
  • :
    Suzhou, Jiangsu 215000, CN
  • :
    201810867252
  • :
    31.7.2018
  • :
    CN
  • :
    CN2019097028
  • :
    22.7.2019
  • :
    A61K 31/4184, A61K 39/395